Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model

Lewis, 2006, Pathophysiologically based treatment interventions in schizophrenia, Nature Med., 12, 1016, 10.1038/nm1478

Ross, 2006, Neurobiology of schizophrenia, Neuron, 52, 139, 10.1016/j.neuron.2006.09.015

Insel, 2006, Cure therapeutics and strategic prevention: raising the bar for mental health research, Mol. Psychiatry, 11, 11, 10.1038/sj.mp.4001777

Coyle, 2006, Glutamate and schizophrenia: beyond the dopamine hypothesis, Cell. Mol. Neurobiol., 26, 365, 10.1007/s10571-006-9062-8

Javitt, 1991, Recent advances in the phencyclidine model of schizophrenia, Am. J. Psychiatry, 148, 1301, 10.1176/ajp.148.10.1301

Krystal, 1994, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch. Gen. Psychiatry, 51, 199, 10.1001/archpsyc.1994.03950030035004

Chumakov, 2002, Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia, Proc. Natl Acad. Sci. USA, 99, 13675, 10.1073/pnas.182412499

Schumacher, 2004, Examination of G72 and D-amino acid oxidase as genetic risk factor for schizophrenia and bipolar affective disorder, Mol. Psychiatry, 9, 203, 10.1038/sj.mp.4001421

Morita, 2006, A genetic variant of the serine racemase gene is associated with schizophrenia, Biol. Psychiatry, 61, 1200, 10.1016/j.biopsych.2006.07.025

Corvin, 2007, Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample, Am. J. Med. Genet. B Neuropsychiatr. Genet., 144B, 949, 10.1002/ajmg.b.30452

Madeira, 2008, Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia, Schizophr. Res., 101, 76, 10.1016/j.schres.2008.02.002

Wolosker, 1999, Purification of serine racemase: Biosynthesis of the neuromodulator D-serine, Proc. Natl Acad. Sci. USA, 96, 721, 10.1073/pnas.96.2.721

Bendikov, 2007, A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia, Schizophr. Res., 90, 41, 10.1016/j.schres.2006.10.010

Hashimoto, 2003, Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N -methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia, Arch. Gen. Psychiatry, 60, 572, 10.1001/archpsyc.60.6.572

Clements, 1991, Activation kinetics reveal the number of glutamate and glycine binding sites on the N -methyl-D-aspartate receptor, Neuron, 7, 605, 10.1016/0896-6273(91)90373-8

Johnson, 1987, Glycine potentiates the NMDA response in cultured mouse brain neurons, Nature, 325, 529, 10.1038/325529a0

Matsui, 1995, Functional comparison of D-serine and glycine in rodents: the effects on cloned NMDA receptors and the extracellular concentration, J. Neurochem., 65, 454, 10.1046/j.1471-4159.1995.65010454.x

Fuchs, 2005, D-amino acids in the central nervous system in health and disease, Mol. Genet. Metab., 85, 168, 10.1016/j.ymgme.2005.03.003

Panatier, 2006, Glia-derived D-serine controls NMDA receptor activity and synaptic memory, Cell, 125, 775, 10.1016/j.cell.2006.02.051

Shleper, 2005, D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices, J. Neurosci., 25, 9413, 10.1523/JNEUROSCI.3190-05.2005

Williams, 2006, Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons, Glia, 53, 401, 10.1002/glia.20300

Yoshikawa, 2006, Expression of the mRNA and protein of serine racemase in primary cultures of rat neurons, Eur. J. Pharmacol., 548, 74, 10.1016/j.ejphar.2006.07.029

Schell, 1997, D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors, J. Neurosci., 17, 1604, 10.1523/JNEUROSCI.17-05-01604.1997

Panizzutti, 2005, The pharmacological stimulation of NMDA receptors via co-agonist site: an fMRI study in the rat brain, Neurosci. Lett., 380, 111, 10.1016/j.neulet.2005.01.062

Basu, 2008, Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior, Mol. Psychiatry

Hoffman, 2009, Recombinant human serine racemase: enzymologic characterization and comparison with its mouse ortholog, Protein Expr. Purif., 63, 62, 10.1016/j.pep.2008.09.003

Sakuraba, 2005, Molecular characterization of ENU mouse mutagenesis and archives, Biochem. Biophys. Res. Commun., 336, 609, 10.1016/j.bbrc.2005.08.134

Wang, 2003, Spatiotemporal relationships among D-serine, serine racemase, and D-amino acid oxidase during mouse postnatal development, Acta Pharmacol. Sin., 24, 965

Dev, 2006, The schizophrenic faces of Pick1, Trends Pharmacol. Sci., 27, 574, 10.1016/j.tips.2006.09.007

Fujii, 2006, Serine racemase binds to Pick1: potential relevance to schizophrenia, Mol. Psychiatry, 11, 150, 10.1038/sj.mp.4001776

Ellenbroek, 2000, Animal models for the negative symptoms of schizophrenia, Behav. Pharmacol., 11, 223, 10.1097/00008877-200006000-00006

Karlsson, 2008, Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia, Neuropsychopharmacol., 34, 1578, 10.1038/npp.2008.215

Swerdlow, 1994, Assessing the validity of an animal model of deficitent sensorimotor gaiting in schizophrenia patients, Arch. Gen. Psychiatry, 51, 139, 10.1001/archpsyc.1994.03950020063007

Geyer, 2001, Pharmacological studies of prepulse inhibition models sensorimotor gating deficits in schizophrenia: a decade in review, Psychopharmacology, 156, 117, 10.1007/s002130100811

Barnett, 2007, Improvement and decline of cognitive function in schizophrenia over 1 year: a longitudinal investigation using latent growth modelling, BMC Psychiatry, 7, 1, 10.1186/1471-244X-7-16

O'Donnell, 1996, Selective deficits in visual perception and recognition in schizophrenia, Am. J. Psychiatry, 153, 687, 10.1176/ajp.153.5.687

Mandillo, 2003, Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits, Behav. Pharmacol., 14, 533, 10.1097/00008877-200311000-00006

Roullet, 1996, Involvement of glutamatergic and dopaminergic systems in the reactivity of mice to spatial and non-spatial change, Psychopharmacology, 126, 55, 10.1007/BF02246411

Mumby, 2002, Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts, Learn. Mem., 9, 49, 10.1101/lm.41302

Sargolini, 1999, Effects of lesions to the glutamatergic afferents to the nucleus accumbens in the modulation of reactivity to spatial and non-spatial novelty in mice, Neuroscience, 93, 855, 10.1016/S0306-4522(99)00259-6

Arguello, 2006, Modeling madness in mice: one piece at a time, Neuron, 52, 179, 10.1016/j.neuron.2006.09.023

Lipina, 2005, Modulators of the glycine site on NMDA receptors, D-serine and ALX-5407, display similar beneficial effects to clozapine in mouse models of schizophrenia, Psychopharmacology, 179, 54, 10.1007/s00213-005-2210-x

Rajeevan, 2001, Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR, J. Mol. Diagn., 3, 26, 10.1016/S1525-1578(10)60646-0

Huang, 2006, Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis, PLoS Med., 3, e428, 10.1371/journal.pmed.0030428

Warner, 2001, Lower prolactin bioactivity in unmedicated schizophrenic patients, Psychiatry Res., 102, 249, 10.1016/S0165-1781(01)00256-6

Akanji, 2007, Associations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects, Clin. Chem. Lab. Med., 45, 1229, 10.1515/CCLM.2007.265

Davis, 2003, White matter changes in schizophrenia: evidence for myelin-related dysfunction, Arch. Gen. Psychiatry, 60, 443, 10.1001/archpsyc.60.5.443

Danesin, 2006, Ventral neural progenitors switch toward an oligodendroglial fate in response to increased Sonic hedgehog (Shh) activity: involvement of sulfatase 1 in modulating Shh signaling in the ventral spinal cord, J. Neurosci., 26, 5037, 10.1523/JNEUROSCI.0715-06.2006

Nagai, 2003, Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress, FASEB J., 17, 50, 10.1096/fj.02-0448fje

Knapska, 2004, A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK?, Prog. Neurobiol., 74, 183, 10.1016/j.pneurobio.2004.05.007

Tyan, 2008, Serum- and glucocorticoid-inducible kinase 1 enhances zif268 expression through the mediation of SRF and CREB1 associated with spatial memory formation, J. Neurochem., 105, 820, 10.1111/j.1471-4159.2007.05186.x

Yamada, 2005, Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels, Biol. Psychiatry, 57, 1493, 10.1016/j.biopsych.2005.03.018

Gondo, 2008, Trends in large-scale mouse mutagenesis: from genetics to functional genomics, Nat. Rev. Genet., 9, 803, 10.1038/nrg2431

Michaud, 2005, Efficient gene-driven germ-line point mutagenesis of C57BL/6J mice, BMC Genomics, 6, 164, 10.1186/1471-2164-6-164

Chang, 2007, The nonsense-mediated decay RNA surveillance pathway, Annu. Rev. Biochem., 76, 51, 10.1146/annurev.biochem.76.050106.093909

D'Aniello, 1993, Biological role of D-amino acid oxidase and D-aspartate oxidase. Effects of D-amino acids, J. Biol. Chem., 268, 26941, 10.1016/S0021-9258(19)74201-X

Wood, 1996, Formation of D-serine from L-phosphoserine in brain synaptosomes, J. Neurochem., 67, 1485, 10.1046/j.1471-4159.1996.67041485.x

Ohnuma, 2008, Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP), Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 1905, 10.1016/j.pnpbp.2008.07.022

Hashimoto, 2007, Effects of MK-801 on the expression of serine racemase and D-amino acid oxidase mRNAs and on the D-serine levels in rat brain, Eur. J. Pharmacol., 555, 17, 10.1016/j.ejphar.2006.09.062

Kim, 2005, Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration, Proc. Natl Acad. Sci. USA, 102, 2105, 10.1073/pnas.0409723102

Beneyto, 2006, Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia, Synapse, 60, 585, 10.1002/syn.20329

Foltyn, 2005, Serine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activity, J. Biol. Chem., 280, 1754, 10.1074/jbc.M405726200

Dunlop, 2005, Regulation of serine racemase activity by amino acids, Brain Res. Mol. Brain Res., 133, 208, 10.1016/j.molbrainres.2004.10.027

Brodkin, 2004, Social approach-avoidance behavior of inbred mouse strains towards DBA/2 mice, Brain Res., 1002, 151, 10.1016/j.brainres.2003.12.013

O'Tuathaigh, 2007, Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia risk gene neuregulin 1, Neuroscience, 147, 18, 10.1016/j.neuroscience.2007.03.051

Braff, 1992, Gating and habituation of the startle reflex in schizophrenic patients, Arch. Gen. Psychiatry, 49, 206, 10.1001/archpsyc.1992.01820030038005

Wong, 1997, Neurocognitive deficits and neurological signs in schizophrenia, Schizophr. Res., 23, 139, 10.1016/S0920-9964(96)00095-3

Chan, 2008, Neurological soft signs as candidate endophenotypes for schizophrenia: a shooting star or a Northern star?, Neurosci. Biobehav. Rev., 32, 957, 10.1016/j.neubiorev.2008.01.005

Murphy, 2006, Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review, Schizophr. Res., 88, 5, 10.1016/j.schres.2006.07.002

Heresco-Levy, 2005, D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia, Biol. Psychiatry, 57, 577, 10.1016/j.biopsych.2004.12.037

Evins, 2002, D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia, Schizophr. Res., 56, 19, 10.1016/S0920-9964(01)00220-1

Heresco-Levy, 1999, Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia, Arch. Gen. Psychiatry, 56, 29, 10.1001/archpsyc.56.1.29

Tsai, 1998, D-serine added to antipsychotics for the treatment of schizophrenia, Biol. Psychiatry, 44, 1081, 10.1016/S0006-3223(98)00279-0

Wu, 2004, Induction of serine racemase expression and D-serine release from microglia by amyloid beta-peptide, J. Neuroinflammation, 1, 2, 10.1186/1742-2094-1-2

Martineau, 2006, D-serine signalling in the brain: friend and foe, Trends Neurosci., 29, 481, 10.1016/j.tins.2006.06.008

Adage, 2008, In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties, Eur. Neuropsychopharmacol., 18, 200, 10.1016/j.euroneuro.2007.06.006

Duffy, 2008, D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning, Neuropsychopharmacology, 33, 1004, 10.1038/sj.npp.1301486

Wolosker, 2008, D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration, FEBS J., 275, 3514, 10.1111/j.1742-4658.2008.06515.x

Matsuoka, 2008, Effect of MK-801 on gene expressions in the amygdala of rats, Synapse, 62, 1, 10.1002/syn.20455

Krügel, 2006, Transcriptional response to the neuroleptic-like compound Ampullosporin A in the rat ketamine model, J. Neurochem., 97, 74, 10.1111/j.1471-4159.2005.03621.x

Giannakopoulou, 2000, NMDA receptor mediated changes in IGF-II gene expression in the rat brain after injury and the possible role of nitric oxide, Neuropathol. Appl. Neurobiol., 26, 513, 10.1046/j.0305-1846.2000.00286.x

Lamas, 2007, D-serine regulates CREB phosphorylation induced by NMDA receptor activation in Müller glia from the retina, Neurosci. Lett., 427, 55, 10.1016/j.neulet.2007.09.009

Aguilar, 1997, Interactions between N-methyl-D-aspartate, nitric oxide and serotonin in the control of prolactin secretion in prepubertal male rats, Eur. J. Endocrinol., 137, 99, 10.1530/eje.0.1370099

Goltsov, 2006, Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia, Mol. Psychiatry, 11, 325, 10.1038/sj.mp.4001801

Strohmaier, 2007, No association between the serine racemase gene (SRR) and schizophrenia in a German case-control sample, Psychiatr. Genet., 17, 125, 10.1097/YPG.0b013e3280143e43

Forrest, 1994, Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death, Neuron, 13, 325, 10.1016/0896-6273(94)90350-6

Sasabe, 2007, D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis, EMBO J., 26, 4149, 10.1038/sj.emboj.7601840

Fick, 2009, Hypothalamic preproghrelin gene expression is repressed by insulin via both PI3-K/Akt and ERK1/2 MAPK pathways in immortalized, hypothalamic neurons, Neuroendocrinol., 89, 267, 10.1159/000167698

Labrie, 2008, Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice, Learn. Mem., 16, 28, 10.1101/lm.1112209

Miyakawa, 2001, Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components, Hippocampus, 11, 763, 10.1002/hipo.1092

Wersinger, 2002, Vasopressin V1b receptor knockout reduces aggressive behavior in male mice, Mol. Psychiatry, 7, 975, 10.1038/sj.mp.4001195

Soleimani, 2008, Beta N-acetylglucosaminyltransferase V (Mgat5) deficiency reduces the depression-like phenotype in mice, Genes Brain Behav., 7, 334, 10.1111/j.1601-183X.2007.00358.x

Labrie, 2008, Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors, Pharmacol. Biochem. Behav., 91, 610, 10.1016/j.pbb.2008.09.016

Labrie, 2008, Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia, Psychopharmacol., 200, 217, 10.1007/s00213-008-1196-6

Boutros, 2008, Transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in liver: comparison of rat and mouse, BMC Genomics, 9, 419, 10.1186/1471-2164-9-419

Dunning, 2007, Beadarray: R classes and methods for Illumina bead-based data, Bioinformatics, 23, 2183, 10.1093/bioinformatics/btm311

Lahiri, 1991, A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies, Nucleic Acids Res., 19, 5444, 10.1093/nar/19.19.5444

Martucci, 2006, N -methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels, Schizophr. Res., 84, 214, 10.1016/j.schres.2006.02.001

Wong, 2005, Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder, Schizophr. Res., 78, 137, 10.1016/j.schres.2005.06.009